Search | Clinical Trials Finder

The live registry is temporarily unavailable. These stored records may be incomplete or out of date. Check the official record for current status and contact information.

ClinicalTrials.gov public records Last synced Oct 19, 2026, 6:15 PM EDT

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2449–2472 of 4,251 matching trials from the local directory fallback.

Filters: Intervention: placebo Clear all

Conditions: Knee Arthropathy
Interventions: Placebo, Tranexamic acid (TXA); Drug
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 350 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: New York, New York

Conditions: Multiple Sclerosis
Interventions: 1000mg acetaminophen or placebo; Drug
Lead sponsor: Hunter College of City University of New York; Other
Eligibility: 18 Years to 65 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: New York, New York

Conditions: PGM1-CDG - Phosphoglucomutase 1-Related Congenital Disorder of Glycosylation
Interventions: AVTX-801, Placebo; Drug
Lead sponsor: Eva Morava-Kozicz; Other
Eligibility: 18 Years to 60 Years
Enrollment: 8 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Dementia With Lewy Bodies
Interventions: Placebo, Terazosin Hydrochloride; Other · Drug
Lead sponsor: Qiang Zhang; Other
Eligibility: 0 Years to 90 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Iowa City, Iowa

Conditions: Clinically Isolated Syndrome, CNS Demyelinating, Demyelinating Diseases, Demyelination; Corpus Callosum, Multiple Sclerosis Acute and Progressive, Multiple Sclerosis Brain Lesion
Interventions: Clemastine Fumarate, Placebo; Drug
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Alzheimer's Disease Dementia, Alzheimer's Disease Diagnosis, Alzheimer's Disease and Related Dementias, Dementia (Diagnosis), Dementia MCI (Mild Cognitive Impairment), Early Stages of Cognitive Decline, Mild Cognitive Impairment (MCI), Parkinson's Disease, Parkinson's Disease (PD), Parkinson's Disease With Wearing-off Motor Fluctuations
Interventions: Control - Placebo Comparator, Stem Cell Therapy - Experimental, Structured wellness care, Wearable brain-computer interface devices; Other · Biological · Behavioral + 1 more
Lead sponsor: Noah Tech, Corp.; Industry
Eligibility: 55 Years and older
Enrollment: 600 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Palisades Park, New Jersey

Conditions: Sickle Cell Crisis, Sickle Cell Disease
Interventions: Ketamine hydrochloride injection, Placebo; Drug · Other
Lead sponsor: Boston Children's Hospital; Other
Eligibility: 6 Years to 24 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Brookline, Massachusetts

Conditions: Obesity & Overweight
Interventions: Placebo, Redefine; Dietary Supplement
Lead sponsor: Nature's Sunshine Products, Inc.; Industry
Eligibility: 35 Years to 65 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026
U.S. locations: 1
States / cities: Lehi, Utah

Conditions: Perimenopause, Women Health
Interventions: Placebo Capsule, Shatavari (Asparagus racemosus) Root Extract; Other · Dietary Supplement
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 40 Years to 45 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Premenstrual Syndrome, Women Health
Interventions: Placebo Capsule, Shatavari Root Extract; Other · Dietary Supplement
Lead sponsor: SF Research Institute, Inc.; Network
Eligibility: 18 Years to 40 Years · Female only
Enrollment: 60 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Clostridioides Difficile Infection, Inflammatory Bowel Diseases
Interventions: Placebo, Xylitol; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years and older
Enrollment: 99 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2033
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Stage 1 Diabetes Mellitus, Type 1
Interventions: Placebo, Semaglutide; Drug
Lead sponsor: Children's Hospital Medical Center, Cincinnati; Other
Eligibility: 12 Years to 70 Years
Enrollment: 15 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Cincinnati, Ohio

Conditions: Frostbite
Interventions: Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum, Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum; Drug
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Breast Cancer, HER-2 Positive Breast Cancer
Interventions: Placebo control, Resistant Potato Starch; Dietary Supplement
Lead sponsor: University of Vermont Medical Center; Other
Eligibility: 18 Years and older · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 1
States / cities: Burlington, Vermont

Conditions: Aging, Postmenopause
Interventions: Mitoquinone (MitoQ), Placebo; Dietary Supplement
Lead sponsor: Colorado State University; Other
Eligibility: 60 Years and older · Female only
Enrollment: 86 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Fort Collins, Colorado

Conditions: Gastrointestinal Symptoms, Inflammation
Interventions: Multi-Strain Postbiotic, Placebo; Dietary Supplement
Lead sponsor: Lindenwood University; Other
Eligibility: 18 Years to 55 Years
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Saint Charles, Missouri

Conditions: Obstructive Sleep Apnea (OSA), Opioids
Interventions: Morphine p.o., Placebo; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 65 Years
Enrollment: 26 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Early Life Trauma, Major Depressive Diorder
Interventions: Lumateperone 42 mg, Placebo; Drug · Other
Lead sponsor: University of Texas at Austin; Other
Eligibility: 21 Years to 70 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Cardiovascular Diseases, Energy Expenditure, Insulin Sensitivity/Resistance, Metabolic Disease, Metabolism, Obesity
Interventions: Insulin Sensitivity Test, MRI-PET Scan for Brown Adipose Tissue Volume Assessment, Placebo, Resting Energy and Exercise Energy Expenditure Assessment, Vericiguat 10 MG, White Adipose Tissue Biopsy; Other · Drug
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years to 80 Years
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: NAFLD, Non-Alcoholic Fatty Liver Disease, Pediatric NAFLD
Interventions: Empagliflozin 10 MG, Placebo Oral Tablet; Drug
Lead sponsor: Justin Ryder; Other
Eligibility: 12 Years to 20 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Drug Liking
Interventions: Amisulpride, Placebo; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Palo Alto, California

Conditions: Macular Telangiectasia Type 2 (MacTel)
Interventions: L-serine, Placebo; Drug · Other
Lead sponsor: The Lowy Medical Research Institute Limited; Other
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 4
States / cities: La Jolla, California • Ann Arbor, Michigan • Cleveland, Ohio + 1 more

Conditions: Stem Cell Surveillance
Interventions: Anthocyanin-rich berry extract, Anthocyanin-rich flower/leaf extract, Berry /leaf blend, Placebo; Dietary Supplement
Lead sponsor: Natural Immune Systems Inc; Other
Eligibility: 18 Years to 75 Years
Enrollment: 48 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Klamath Falls, Oregon

Conditions: Addiction, Insomnia, Nicotine, Sleep, Smoking, Substance Use Disorders, Tobacco
Interventions: Daridorexant 50 mg, Placebo; Drug · Other
Lead sponsor: Legacy Health System; Other
Eligibility: 18 Years to 55 Years
Enrollment: 44 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Portland, Oregon

Search by objective public record fields.

Extended Oral Tranexamic Acid After Primary Total Knee Arthroplasty

Effect of Acetominophen an Gait Fatigue in Multiple Sclerosis

Evaluating the Efficacy and Safety of D-galactose in PGM1-CDG (AVTX-801)

Terazosin for Dementia With Lewy Bodies

Assessing Changes in Multi-parametric MRI in Patients With Acute Demyelinating Lesions Taking Clemastine Fumarate as a Myelin Repair Therapy

Mild Cognitive Impairment Community Screening and Early Intervention Via Stem Cell Therapy and Wearable Brain Computer Interface Device.

Optimal Timing of Ketamine Initiation for SCD Pain

Safety and Tolerability of a Nutritional Formula Designed to Aid in Maintenance of Muscle During Periods of Caloric Restriction in Adults

Shatavari Root Extract for Perimenopausal Symptoms

Efficacy and Safety of Shatavari Root Extract for Premenstrual Syndrome in Women

Xylitol Use for Decolonization of C. Difficile in Patients With IBD

GLP-1 RA for Stage 1 Type 1 Diabetes

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

Gut Microbiome Changes During Abemaciclib Therapy in Breast Cancer

Oral Antioxidant Therapy Targeted to the Mitochondria for Improving Brain Artery Health in Postmenopausal Women

Evaluating the Ability of a Multi-Strain Postbiotic to Impact Inflammation, Immune Components, Gastrointestinal Symptoms, Recovery, Anxiety, and Intestinal Permeability

Impacts of Opioids on Respiratory Drive During Sleep

Neurocircuitry Mechanisms and Efficacy of Lumateperone as Adjunctive Therapy for Major Depressive Disorder and History of Early Life Abuse

VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

SGLT2 Inhibitors as a Novel Treatment for Pediatric Non-Alcoholic Fatty Liver Disease

Characterizing Drug Liking During Drug Administration in Peri-procedural Clinical Settings

Study of Serine Supplementation to Protect Vision in MacTel

Acute Effects on Stem Cell Surveillance

Impact of Daridorexant on Sleep, Daytime Alertness, and Smoking